Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes

被引：11

作者：

Tamburini, J. ^{[1
]}

Elie, C. ^{[2
]}

Park, S. ^{[1
]}

Beyne-Rauzy, O. ^{[3
]}

Gardembas, M. ^{[4
]}

Berthou, C. ^{[5
]}

Mahe, B. ^{[6
]}

Sanhes, L. ^{[7
]}

Stamatoullas, A. ^{[8
]}

Vey, N. ^{[9
]}

Aouba, A.

Slama, B. ^{[10
]}

Quesnel, B. ^{[11
]}

Vekhoff, A. ^{[13
]}

Sotto, J. J. ^{[12
]}

Vassilief, D. ^{[1
]}

Al-Nawakil, C. ^{[1
]}

Fenaux, P. ^{[14
]}

Dreyfus, F. ^{[1
]}

Bouscary, D. ^{[1
]}

机构：

[1] Hop Cochin, Dept Haematol, Paris, France

[2] Univ Paris 05, Dept Biostat, F-75270 Paris 06, France

[3] Hop Purpan, Dept Hematol Odile, Toulouse, France

[4] Ctr Hosp Angers, Dept Hematol Martine, Angers, France

[5] Hop Brest, Dept Hematol Christian, Brest, France

[6] Ctr Hosp Nantes, Dept Hematol, Nantes, France

[7] Ctr Hosp Perpignan, Dept Hematol, Perpignan, France

[8] Ctr Hosp Rouen, Dept Hematol Aspasia, Rouen, France

[9] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[10] Ctr Hosp Avignon, Dept Hematol, Avignon, France

[11] Ctr Hosp Lille, Dept Hematol, Lille, France

[12] Ctr Hosp Grenoble, Dept Hematol, Grenoble, France

[13] Hop Hotel Dieu, Dept Hematol, F-75181 Paris, France

[14] Hop Avicenne, Dept Hematol, Bobigny, France

来源：

LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期

关键词：

INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; ANEMIA; PROPOSAL;

D O I：

10.1016/j.leukres.2008.06.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：547 / 550

页数：4

共 50 条

[1] Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes
Ghaderi, Afshin
Nodehi, Sayyed Reza Safaee
Bakhtiari, Tahereh
Aslani, Mona
Aghazadeh, Zahra
Matsuo, Hidenori
Rehm, Bernd H. A.
Cuzzocrea, Salvatore
Mirshafiey, Abbas
JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07) : 879 - 888
[2] How low risk are low risk myelodysplastic syndromes?
DeZern, Amy E.
Dalton, William Brian
EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (01) : 15 - 24
[3] Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies
Molica, Matteo
Rossi, Marco
EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (04) : 233 - 241
[4] The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances
Randall, Michael P.
DeZern, Amy E.
CANCER JOURNAL, 2023, 29 (03) : 152 - 159
[5] Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
Santini, Valeria
Valcarcel, David
Platzbecker, Uwe
Komrokji, Rami S.
Cleverly, Ann L.
Lahn, Michael M.
Janssen, Jan
Zhao, Yumin
Chiang, Alan
Giagounidis, Aristoteles
Guba, Susan C.
Gueorguieva, Ivelina
Girvan, Allicia C.
Ferreira, Mariana da Silva
Bhagat, Tushar D.
Pradhan, Kith
Steidl, Ulrich
Sridharan, Ashwin
Will, Britta
Verma, Amit
CLINICAL CANCER RESEARCH, 2019, 25 (23) : 6976 - 6985
[6] Luspatercept as first line in transfusiondependant very low to intermediate risk myelodysplastic syndromes
Tauveron-Jalenques, Urbain
Requena, Gaspar Aspas
BULLETIN DU CANCER, 2025, 112 (02) : 113 - 114
[7] Past, present and future in low-risk myelodysplastic syndrome
Toprak, Selami Kocak
FRONTIERS IN MEDICINE, 2022, 9
[8] Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies
Trivedi, Gaurang
Inoue, Daichi
Zhang, Lingbo
TRENDS IN MOLECULAR MEDICINE, 2021, 27 (10) : 990 - 999
[9] Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function
Roberto Castelli
Giorgio Lambertenghi Deliliers
Riccardo Colombo
Guido Moreo
Paolo Gallipoli
Giuseppe Pantaleo
Annals of Hematology, 2014, 93 : 1523 - 1529
[10] Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents
Castelli, Roberto
Schiavon, Riccardo
Rossi, Valentina
Deliliers, Giorgio Lambertenghi
MEDICAL ONCOLOGY, 2018, 35 (05)

← 1 2 3 4 5 →